Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7)
Background: This analysis evaluated patient-reported outcomes (PROs) to assess health-related quality of life (HRQoL) in the phase III MONALEESA-7 trial, which previously demonstrated improvements in progression-free survival (PFS) and overall survival (OS) with ribociclib (cyclin-dependent kinase 4...
Main Authors: | Nadia Harbeck, Fabio Franke, Rafael Villanueva-Vazquez, Yen-Shen Lu, Debu Tripathy, Louis Chow, Govind K Babu, Young-Hyuck Im, David Chandiwana, Anil Gaur, Brad Lanoue, Karen Rodriguez-Lorenc, Aditya Bardia |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2020-07-01
|
Series: | Therapeutic Advances in Medical Oncology |
Online Access: | https://doi.org/10.1177/1758835920943065 |
Similar Items
-
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study
by: Peter A. Fasching, et al.
Published: (2020-12-01) -
Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial
by: Gabriel N. Hortobagyi
Published: (2018-10-01) -
Cost-Effectiveness of Adding Ribociclib to Endocrine Therapy for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Among Premenopausal or Perimenopausal Women
by: Eunae Jeong, et al.
Published: (2021-05-01) -
Cost-effectiveness Analysis of Ribociclib plus Letrozole versus Palbociclib plus Letrozole in the United Kingdom
by: Gaurav Suri, et al. -
Clinical aspects of the use of ribociclib
by: A. A. Markovich, et al.
Published: (2020-07-01)